Fig 1.
Clinical composite of the 11 study horses with biopsy confirmed periocular squamous cell carcinoma (PSCC).
Each horse received perilesional injections of IFNα2b for PSCC every two weeks starting at time 0 for a total of four to six injections. Responders had greater than 50% reduction in tumor size after completion of treatment. Pre- and post-perilesional IFNα2b treatment photos taken at each patient’s initial ophthalmic examination (a) and last follow-up examination (b).
Table 1.
Study population data, response to treatment, number of injections, incidence of local reactions, follow-up, additional intervention data for 11 horses (12 eyes) receiving perilesional injections of IFNα2b for periocular squamous cell carcinoma (PSCC) tumors every two weeks starting at time 0 for a total of four to six injections.
Fig 2.
Optical density (OD) at 450 nm measurement of serum antibodies to interferon α2b in 11 horses (each represented by a different color in the line graphs) receiving perilesional injections of human recombinant IFNα2b for periocular squamous cell carcinoma tumors every two weeks starting at time 0 for a total of four to six injections.
Responders had greater than 50% reduction in tumor size after completion of treatment. Each arrow along the x axis represents the time of perilesional treatment and the mean value of untreated normal serum is represented with dotted line. No significant difference in mean ± standard deviation IFNα2b serum antibodies was found between responders and non-responders at two, four, or six week post treatment initiation. Later time points included insufficient data for comparison.